Treatment outcome of PD-1 immune checkpoint inhibitor in Asian metastatic melanoma patients: correlative analysis with PD-L1 immunohistochemistry Jinhyun ChoSoomin AhnJeeyun Lee PRECLINICAL STUDIES 04 August 2016 Pages: 677 - 684
The novel kinase inhibitor ponatinib is an effective anti-angiogenic agent against neuroblastoma Sarah B. WhittleKalyani PatelPeter E. Zage PRECLINICAL STUDIES 01 September 2016 Pages: 685 - 692
Comparative effects of doxorubicin and a doxorubicin analog, 13-deoxy, 5-iminodoxorubicin (GPX-150), on human topoisomerase IIβ activity and cardiac function in a chronic rabbit model Nicole E. FrankBarry J. CusackRichard D. Olson PRECLINICAL STUDIES 31 August 2016 Pages: 693 - 700
A retrospective analysis of 14 consecutive Chinese patients with unresectable or metastatic alveolar soft part sarcoma treated with sunitinib Ting LiLei WangChunmeng Wang PRECLINICAL STUDIES 08 September 2016 Pages: 701 - 706
Propolis extracts from the northern region of Thailand suppress cancer cell growth through induction of apoptosis pathways Supakit Khacha-anandaKhajornsak TragoolpuaYingmanee Tragoolpua PRECLINICAL STUDIES 21 September 2016 Pages: 707 - 722
New water-soluble palladium(II) complexes of lidocaine and phenylcyanamide derivative ligands: cytotoxicity and cellular response mechanisms Leila TabriziHossein Chiniforoshan PRECLINICAL STUDIES 19 September 2016 Pages: 723 - 732
A phase I trial of cabozantinib and gemcitabine in advanced pancreatic cancer David B. ZhenKent A. GriffithMark M. Zalupski PHASE I STUDIES 21 July 2016 Pages: 733 - 739
A phase Ib dose-escalation study of the MEK inhibitor trametinib in combination with the PI3K/mTOR inhibitor GSK2126458 in patients with advanced solid tumors J. E. Grilley-OlsonP. L. BedardJ. R. Infante PHASE I STUDIES 23 July 2016 Pages: 740 - 749
Phase I study of NK105, a nanomicellar paclitaxel formulation, administered on a weekly schedule in patients with solid tumors Hirofumi MukaiKen KatoYoshihiro Nambu PHASE I STUDIES Open access 05 September 2016 Pages: 750 - 759
Clinical, pharmacodynamic and pharmacokinetic results of a prospective phase II study on oral metronomic vinorelbine and dexamethasone in castration-resistant prostate cancer patients Teresa Di DesideroLisa DerosaGuido Bocci PHASE II STUDIES 24 August 2016 Pages: 760 - 770
Sunitinib maintenance therapy after response to docetaxel in metastatic castration resistant prostate cancer (mCRPC) Sunil ParimiMisha EliasziwBernhard J. Eigl PHASE II STUDIES 26 August 2016 Pages: 771 - 776
Comprehensive analysis of clinical development and regulatory submission promotion schemes for oncologic drugs as the Japanese national projects Sumimasa NagaiKeiya Ozawa PHASE III STUDIES 19 August 2016 Pages: 777 - 791
Sunitinib-induced sudden hearing loss Kathleen DekeisterEmmanuelle GraillotThomas Walter SHORT REPORT 30 July 2016 Pages: 792 - 793
Adding checkpoint inhibitors to tyrosine kinase inhibitors targeting EGFR/ALK in non-small cell lung cancer: a new therapeutic strategy Samer TabchiHampig Raphael KourieJoseph Kattan SHORT REPORT 25 August 2016 Pages: 794 - 796
Successful treatment with afatinib after gefitinib- and erlotinib-induced hepatotoxicity Hiroto UedaHidetoshi HayashiKazuhiko Nakagawa SHORT REPORT 23 August 2016 Pages: 797 - 799